Skip to main content

NervGen Pharma Corp.

corporate_fare Company Profile

NervGen Pharma Corp.

NGEN·NASDAQ·Life Sciences·CIK 0001751912

NervGen Pharma Corp. is a biotechnology company focused on discovering, developing, and commercializing pharmaceutical treatments to repair the nervous system following neurotrauma and neurologic disease. The company's primary product candidate is NVG-291, which is currently in a Phase 1b/2a clinical trial. This trial is evaluating NVG-291 for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease. Another product candidate, NVG-300, is in preclinical studies for ischemic stroke, amyotrophic lateral sclerosis, and a confirmatory SCI study. NervGen Pharma Corp. holds a licensing agreement with Case Western Reserve University, granting it rights to develop and commercialize a patented technology that shows therapeutic potential for spinal cord injury and other conditions involving nerve damage. The company was incorporated in 2017 and operates from its headquarters in Vancouver, Canada.

NervGen Pharma Corp. (NASDAQ:NGEN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 25 items for NGEN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for NGEN spans 6-K, 6-K/A, 40-F/A, F-10.

Recent high-impact activity:

  • NervGen Posts Q3 2026 Results With C$80.1M Cash; Material Weakness Still Unremediated
  • FDA Grants Breakthrough Therapy Designation to NVG-291 for Chronic Spinal Cord Injury
  • NervGen Refiles Q2 2026 Interim Financials, Restating Loss to Income on Warrant Fix
  • NervGen Files Amended 40-F with Restated Financials and Material Weakness Disclosure
  • NervGen to Restate Financials on Non-Cash Accounting Adjustments

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$44.21M
Diluted EPS
-$0.61
Op. Cash Flow
-$19.5M
Cash & Equivalents
$22.07M
Debt / Equity
0.00×
Shares Outstanding
79.65M sh
Source: 40-F · filed 2026-10-16 · accession 0001104659-26-116627

Short Interest & Short Volume

11.21 days to cover

FINRA reported short interest of 4,861,715 shares in NGEN as of the October 30, 2026 settlement, a 4.4% decrease from the prior period — about 11.2 days to cover at its recent average daily volume. On November 20, 2026, 51.2% of NGEN volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)4,861,715 shares as of October 30, 2026
Change vs prior period▼ 4.4%
Days to cover11.21 at avg daily volume of 433,689
Daily short volume (FINRA facilities)51.2% of 400,232 shares on November 20, 2026
5-day average short volume54.1%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for NGEN, detected from its recent SEC filings · based on capital-structure filings through 2026-07-02.

ATM program1 shelf registration

New ATM Program Established · Significant Potential Dilution

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Insider Transactions

NGEN files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with N →
$1.95 +5.69% today
52-week range · as of 2026-11-16 $1.28 – $6.3
Market cap
$198.55M
Volume
666.8K (1.0× avg)
3-mo avg 687.4K
Live data · 2026-11-21 22:22 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed NGEN - Latest Insights

NGEN
Nov 16, 2026, 4:30 PM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.95
Real-time Price: $1.95 info
Change: $0 (0%) info
Market Cap: $198.552M info
NGEN
Nov 12, 2026, 7:15 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.52
Real-time Price: $1.95 info
Change: +$0.430 (+28%) info
Market Cap: $198.552M info
NGEN
Oct 16, 2026, 4:31 PM EDT
Filing Type: 6-K/A
Importance Score:
8
Price at Filing: $1.59
Real-time Price: $1.95 info
Change: +$0.360 (+23%) info
Market Cap: $198.552M info
NGEN
Oct 16, 2026, 4:30 PM EDT
Filing Type: 40-F/A
Importance Score:
8
Price at Filing: $1.59
Real-time Price: $1.95 info
Change: +$0.360 (+23%) info
Market Cap: $198.552M info
NGEN
Sep 25, 2026, 4:31 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $1.86
Real-time Price: $1.95 info
Change: +$0.090 (+5%) info
Market Cap: $198.552M info
NGEN
Sep 25, 2026, 4:30 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.86
Real-time Price: $1.95 info
Change: +$0.090 (+5%) info
Market Cap: $198.552M info
NGEN
Aug 13, 2026, 7:32 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $1.83
Real-time Price: $1.95 info
Change: +$0.120 (+7%) info
Market Cap: $198.552M info
NGEN
Aug 13, 2026, 7:31 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.83
Real-time Price: $1.95 info
Change: +$0.120 (+7%) info
Market Cap: $198.552M info
NGEN
Jul 02, 2026, 5:23 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $2.12
Real-time Price: $1.95 info
Change: -$0.170 (-8%) info
Market Cap: $198.552M info
NGEN
May 26, 2026, 4:35 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $2.16
Real-time Price: $1.95 info
Change: -$0.2094 (-10%) info
Market Cap: $198.552M info
NGEN
May 26, 2026, 9:26 AM EDT
Filing Type: F-10
Importance Score:
8
Price at Filing: $2.21
Real-time Price: $1.95 info
Change: -$0.260 (-12%) info
Market Cap: $198.552M info
NGEN
May 26, 2026, 7:15 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $2.17
Real-time Price: $1.95 info
Change: -$0.220 (-10%) info
Market Cap: $198.552M info
NGEN
May 22, 2026, 5:24 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $2.09
Real-time Price: $1.95 info
Change: -$0.1403 (-7%) info
Market Cap: $198.552M info
NGEN
May 21, 2026, 11:28 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $2.81
Real-time Price: $1.95 info
Change: -$0.855 (-30%) info
Market Cap: $198.552M info
NGEN
May 21, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.96
Real-time Price: $1.95 info
Change: -$1.01 (-34%) info
Market Cap: $198.552M info
NGEN
May 18, 2026, 4:19 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $3.64
Real-time Price: $1.95 info
Change: -$1.69 (-46%) info
Market Cap: $198.552M info
NGEN
May 15, 2026, 4:28 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $3.57
Real-time Price: $1.95 info
Change: -$1.62 (-45%) info
Market Cap: $198.552M info
NGEN
Apr 27, 2026, 5:05 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $3.98
Real-time Price: $1.95 info
Change: -$2.03 (-51%) info
Market Cap: $198.552M info
NGEN
Apr 27, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.14
Real-time Price: $1.95 info
Change: -$2.19 (-53%) info
Market Cap: $198.552M info
NGEN
Apr 07, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $4.45
Real-time Price: $1.95 info
Change: -$2.50 (-56%) info
Market Cap: $198.552M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets